The effectiveness of aromatherapy inhaler on irritable bowel syndrome (IBS) patients.

A clinical trial to comparison the effectiveness of aromatherapy inhaler of rose essence with placebo (grape seed Oil) in clinical outcomes of irritable bowel syndrome (IBS) patients.

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT2016123031663N1

Enrollment

Registered

2017-02-14

Start date

2017-02-19

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Irritable bowel syndrome. Irritable bowel syndrome

Interventions

Intervention 1: Control group: Irritable bowel syndrome (IBS) patients are revising placebo (grape seed Oil) nose against on non-absorbable paper for 20 minutes twice a day for 4 weeks and evaluation

Treatment - Drugs

Control group: Irritable bowel syndrome (IBS) patients are revising placebo (grape seed Oil) nose against on non-absorbable paper for 20 minutes twice a day for 4 weeks and evaluation of clinical outc

Interventional group: Irritable bowel syndrome (IBS) patients are revising rose essence nose against on non-absorbable paper for 20 minutes twice a day for 4 weeks and evaluation of clinical outcomes

Eligibility

Sex/Gender

All

Age

15 Years to 60 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: Aged between 15 and 60 years; Abdominal pain or discomfort at least three days a month in the past three months; patients with mild-to-moderate IBS; Lack of nasal polyps (NP) or deviated nasal septum (DNS) disease; Having cranial nerve activity with examination; Lack of specific psychiatric diagnoses which led him to be hospitalized. Exclusion criteria: Failure to use the correct fragrance; Drugs, tobacco or hookah addiction; Allergic reaction to essential oils; Using complementary or alternative medicine; Having allergic rhinitis and respiratory diseases.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Clinical outcomes including pain frequency, pain duration, poop's consistency, defecation frequency, etc. Timepoint: 4 weeks after intervention. Method of measurement: Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMahtab Rashidi

Mashhad University of Medical Sciences

Mahtab.rashidi72@yahoo.com+98 51 3760 4106

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026